...
首页> 外文期刊>Journal of Medicinal Chemistry >Discovery of Tarantula Venom-Derived Na(V)1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis
【24h】

Discovery of Tarantula Venom-Derived Na(V)1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced Pruritis

机译:发现蒿属毒液衍生Na(v)1.7抑制JZTX-V肽5-BR-TRP24类似物组合血管炎的全身菌株胰腺炎

获取原文
获取原文并翻译 | 示例

摘要

Inhibitors of the voltage-gated sodium channel Na(V)1.7 are being investigated as pain therapeutics due to compelling human genetics. We previously identified Na(V)1.7-inhibitory peptides GpTx-1 and JzTx-V from tarantula venom screens. Potency and selectivity were modulated through attribute-based positional scans of native residues via chemical synthesis. Herein, we report JzTx-V lead optimization to identify a pharmacodynamically active peptide variant. Molecular docking of peptide ensembles from NMR into a homology model-derived Na(V)1.7 structure supported prioritization of key residues clustered on a hydrophobic face of the disulfide-rich folded peptide for derivatization. Replacing Trp24 with S-Br-Trp24 identified lead peptides with activity in electrophysiology assays in engineered and neuronal cells. 5-Br-Trp24 containing peptide AM-6120 was characterized in X-ray crystallography and pharmacokinetic studies and blocked histamine-induced pruritis in mice after subcutaneous administration, demonstrating systemic Na(V)1.7-dependent pharmacodynamics. Our data suggests a need for high target coverage based on plasma exposure for impacting in vivo end points with selectivity-optimized peptidic Na(V)1.7 inhibitors.
机译:由于引人注目的人类遗传,正在研究电压门控钠通道Na(v)1.7的抑制剂作为疼痛治疗剂。我们以前鉴定了来自狼蛛血液筛查的Na(v)1.7抑制肽GPTX-1和JZTX-V。通过化学合成通过基于物质残留物的基于属性的位置扫描来调节效力和选择性。在此,我们报告JZTX-V铅优化以鉴定药效学活性肽变体。将肽与NMR合并到同源性模型 - 衍生的NA(V)1.7结构中的分子对接,其支持在富含二硫化物的折叠肽的疏水面上聚集的关键残基的优先级排序以进行衍生化。用S-BR-TRP24替代TRP24鉴定的铅肽,其在工程和神经元细胞中的电生理学测定中的活性。 5-BR-TRP24含有肽AM-6120的特征在于X射线晶体学和药代动力学研究,并在皮下施用后阻断组胺诱导的小鼠中的胰腺炎,证明了全身NA(V)1.7依赖性药效学。我们的数据表明,基于血浆暴露的高目标覆盖需要,用于撞击具有选择性优化的肽NA(V)1.7抑制剂的体内终点。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2018年第21期|共13页
  • 作者单位

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Therapeut Discovery 360 Binney St Cambridge MA 02142 USA;

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Neurosci One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Neurosci One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Neurosci One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Neurosci One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Therapeut Discovery 1120 Vet Blvd San Francisco CA 94080 USA;

    Amgen Inc Amgen Res Therapeut Discovery 1120 Vet Blvd San Francisco CA 94080 USA;

    Amgen Inc Amgen Res Neurosci 360 Binney St Cambridge MA 02142 USA;

    Amgen Inc Amgen Res Neurosci One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Pharmacokinet &

    Drug Metab 360 Binney St Cambridge MA 02142 USA;

    Amgen Inc Amgen Res Pharmacokinet &

    Drug Metab 360 Binney St Cambridge MA 02142 USA;

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Neurosci One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

    Amgen Inc Amgen Res Therapeut Discovery One Amgen Ctr Dr Thousand Oaks CA 91320 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号